Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

Original publication

DOI

10.2217/fon-2020-1048

Type

Journal article

Journal

Future Oncol

Publication Date

04/2021

Volume

17

Pages

1449 - 1458

Keywords

ACVR1, JAK inhibitor, Phase III clinical trial, anemia, danazol, hemoglobin, momelotinib, myelofibrosis, transfusion, Activin Receptors, Type I, Administration, Oral, Adult, Benzamides, Clinical Trials, Phase III as Topic, Danazol, Double-Blind Method, Female, Humans, Janus Kinase 1, Janus Kinase 2, Janus Kinase Inhibitors, Male, Middle Aged, Primary Myelofibrosis, Pyrimidines, Randomized Controlled Trials as Topic, Self Administration, Treatment Outcome